| Literature DB >> 27481448 |
Jeanne Palmer1, Jeannine S McCune2, Miguel-Angel Perales3, David Marks4, Joseph Bubalo5, Mohamad Mohty6, John R Wingard7, Angelo Paci8, Moustapha Hassan9, Christopher Bredeson10, Joseph Pidala11, Nina Shah12, Paul Shaughnessy13, Navneet Majhail14, Jeff Schriber15, Bipin N Savani16, Paul A Carpenter17.
Abstract
The Practice Guidelines Committee of the American Society of Blood or Marrow Transplantation (ASBMT) sought to develop an evidence-based review about personalizing busulfan-based conditioning. The Committee sought to grade the relevant published studies (June 1, 2008 through March 31, 2016) according to criteria set forth by the Steering Committee for Evidence Based Reviews from ASBMT. Unfortunately, the published literature was too heterogeneous and lacked adequately powered and sufficiently controlled studies for this to be feasible. Despite this observation, the continued interest in this topic led the Practice Guidelines Committee to develop a list of most frequently asked questions (FAQs) regarding personalized busulfan dosing. This "Considerations" document is a list of these FAQs and their responses, addressing topics of practical relevance to hematopoietic cell transplantation clinicians.Entities:
Keywords: Busulfan; Hematopoietic cell transplantation; Pharmacokinetics; Precision medicine; Therapeutic drug monitoring
Mesh:
Substances:
Year: 2016 PMID: 27481448 DOI: 10.1016/j.bbmt.2016.07.013
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN: 1083-8791 Impact factor: 5.742